A Phase IIa, Open-label, Multiple-Dose Trial to Investigate the Safety and Efficacy of the UB-421 in Asymptomatic HIV-1 Infected Adults
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Semzuvolimab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors United Biomedical
- 19 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 24 Aug 2012 New trial record